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Patient Baseline Characteristics Results
Results (continued) Cost Analysis Results
• Institutional Review Board (IRB)-approved 
• Multi-center, pre- and post-intervention, observational, 
retrospective review, spanning 12 months, of hospitalized adults 
admitted to any one of the eight POR hospitals who received IV 
antibiotics for a UTI
• Pre-Group (Control): 
• January 1, 2019—June 30, 2019
• Post-Group: 
• July 1, 2019—December 31, 2019
• Inclusion Criteria:
• Age ≥ 18yo, hospitalized, received IV 
antibiotics for the indication of a UTI
• Exclusion Criteria:
• Age < 18yo, any bacteremia, concomitant 
infection at a different anatomical site
• Primary Outcome:
• Rate of empiric IV ceftriaxone usage (based on 
administrations) compared to IV anti-
pseudomonal agents, pre- vs. post-AMS 
antibiotic recommendation implementation 
• Secondary Outcomes:
• Average length of hospital stay (LOS)
• 30- and 90-day mortality (Providence patients)
• Days of therapy (DOT) per 1000 patient days
• Cost Analysis: 
• Cost-savings impact for length of hospital stay
• Cost-savings impact for total cost of antibiotic 
by days of therapy
Patient Population
• The total number of patients included was 5,435 and the total 
number of empiric IV antibiotic administrations was 6,504.
• There were more patients and empiric IV antibiotic 
administrations in the Post-Group than in the Pre-Group (2733 
vs. 2702 and 3401 vs. 3103, respectively).
• At baseline, patients were similar in age, gender, race, ethnicity 
and hospital disposition (ICU vs Non-ICU) between the two 
groups.
• Mean age was 66.1 years in the Pre-Group and 65.6 years in the 
Post-Group. 
• The average Charlson Comorbidity Index (CCI) Score was similar 
between the two groups (4.85 in the Pre-Group and 4.71 in the 
Post-Group). 
• Hospital location for empiric IV antibiotic administration was 
similar between the two groups.
• The predominant indication for antibiotic use was for UTI—
Lower.
Outcomes
• The rate of empiric IV ceftriaxone administrations for UTIs, 
compared to other IV anti-pseudomonal agents, increased in the 
Post-Group compared to Pre-Group (87.0% vs. 84.7%, 
respectively). 
• The usage rate (based on administrations) of almost all empiric 
IV anti-pseudomonal agents was decreased in the Post-Group. 
• The average length of hospital stay (excluding patients with LOS 
<1 day) was reduced in the Post-Group compared to the Pre-
Group (6.05 days vs. 6.85 days, respectively).
• Both 30-day and 90-day mortality were reduced in the Post-
Group. 
• The DOT/1000PD in the Post-Group increased for ceftriaxone 
and decreased for Zosyn.
• The total cost of LOS per patient was reduced in the Post-Group 
by $3.9 million compared to the Pre-Group ($63.5 million vs. 
$67.4 million).
• The average cost of LOS per patient was reduced by $4,511 in 
the Post-Group compared to the Pre-Group ($28,865 vs. 
$33,376). 
• There was a total cost-savings, with regard to cost of antibiotic 
by DOT, in the Post-Group.
Study Limitations
• Retrospective, non-randomized study
• Statistical analysis of this study is currently pending
• Data pulled and analyzed based on antibiotic indication
• Study did not include assessment of patient outcomes:
• Treatment failure
• Clinical cure
• Inconsistencies for electronic medical record documentation of 
mortality 
• Unmeasured, confounding variables could have influenced the 
result of physician adherence to guideline-based treatment 
recommendations
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• Urinary tract infections (UTIs) are one of the most common 
indications for prescribing antibiotics in the inpatient setting. 
• Recent literature suggests that not all patients are prescribed 
empiric antibiotics that are adherent to Infectious Diseases 
Society of America (IDSA) guidelines.
• Arguably the most positive, predictable impact on provider 
adherence to guideline-based treatment regimens is achieved 
when evidence-based recommendations are made easily 
accessible.
• The causative organism at the time of diagnosis and initiation of 
antibiotic therapy for a UTI is generally unknown: patients are 
often prescribed broad-spectrum therapy that may be 
unnecessary.
• Inappropriate treatment of infections has been shown to be an 
important determinant of the development of antimicrobial 
resistance, hospital mortality, prolonged hospitalization, 
increased adverse antibiotic effects and increased healthcare 
costs. 
• The IDSA guidelines emphasize the importance of using 
antibiotics to target E. Coli, which is the organism responsible 
for ~75% of UTIs, and tailoring empiric antibiotic selection 
based on local susceptibility data. 
• Susceptibility data from 2019 in the POR demonstrates that the 
E. coli resistance rates to sulfamethoxazole-trimethoprim and 
ciprofloxacin are 19% and 14%, respectively.
• On July 1, 2019, the Providence Oregon Region (POR) 
Antimicrobial Stewardship (AMS) Committee gained P&T 
approval for the release of regional, preferred empiric antibiotic 
recommendations for hospitalized adults with common 
infections, including UTIs. 
• The susceptibility rate of E. coli to ceftriaxone in the POR is 94%, 
making it the preferred, empiric intravenous (IV) agent.
Table 2: Primary outcome
Figure 4: Average cost of hospital stay by month
• We demonstrated that a simple AMS intervention involving the 
dissemination of region-specific empiric treatment 
recommendations was associated with an improvement in 
provider adherence to IDSA guidelines.
• The AMS initiative also showed a reduction in unnecessary broad-
spectrum antibiotic and fluoroquinolone use for UTIs.
• We found that the average length of hospital stay was markedly 
reduced, following the intervention, which resulted in 
approximately $3.9M in cost savings for the POR.
Purpose
• The purpose of this study is to assess the rate of POR provider 
compliance to empiric, regional guidelines before and after the 
implementation of the AMS Committee treatment 
recommendations for UTIs, and evaluate the intervention’s 
financial impact.
Methodology
• Describe the clinical and financial impact of a regional AMS 
intervention on provider adherence to empiric antibiotic 







Age, years, mean 66.1 (range 18-106) 65.6 (range 18-105)
Sex, female, No. (%) 1873 (69.3) 1932 (70.7)
Sex, male, No. (%) 829 (30.7) 800 (29.3)
CCI Score, mean 4.85 4.71
Race, No. (%)
Caucasian 2246 (83.1) 2250 (82.3)
African American 47 (1.73) 65 (2.38)
Asian 64 (2.36) 77 (2.81)
Ethnicity, No. (%)
Hispanic or Latino 189 (6.99) 171 (6.25)







Hospital A 1040 (33.52) 1060 (31.2)
Hospital B 689 (22.2) 765 (22.5)
Hospital C 226 (7.28) 258 (7.6)
Hospital D 71 (2.29) 109 (3.2)
Hospital E 202 (6.51) 287 (8.44)
Hospital F 569 (18.34) 635 (18.67)
Hospital G 86 (2.77) 76 (2.23)
Hospital H 220 (7.09) 211 (6.2)
Primary Indication, No. (%)
UTI—Lower 2037 (65.6) 2251 (66.2)
UTI—Upper 1066 (34.4) 1150 (33.8)
Patient Disposition, No. (%)
ICU 549 (17.6) 588 (17.3)
Non-ICU 2554 (82.4) 2812 (82.7) 
Abbreviations: CCI = Charlson Comorbidity Index; ICU = Intensive Care Unit 
Figure 3: Length of hospital stay by month








Ceftriaxone 2628 (84.7) 2958 (87.0) +2.30%
Zosyn 189 (6.09) 147 (4.32) -1.77%
Meropenem 65 (2.09) 68 (2.0) -0.09%
Ceftazidime 12 (0.39) 7 (0.21) -0.18%
Cefepime 55 (1.77) 77 (2.26) +0.49%
Ciprofloxacin 117 (3.77) 109 (3.2) -0.57%
Levofloxacin 37 (1.19) 35 (1.03) -0.16%
Abbreviations: IV = Intravenous; Zosyn = Piperacillin-tazobactam















30-Day Mortality, No. (%) 130 (4.84) 110 (4.02) -0.82%
90-Day Mortality, No. (%) 218 (8.1) 200 (7.31) -0.79%






Ceftriaxone 336.61 377.1 +10.74%
Zosyn 86.67 79.23 -9.39%
Meropenem 34.29 35.30 +2.87%
Ceftazidime 4.49 2.55 -76.0%
Cefepime 30.75 32.68 +5.92%
Ciprofloxacin 37.69 39.5 +4.58%
Levofloxacin 11.65 7.35 -58.56%
Abbreviations: LOS = Length of Stay; DOT = Days of Therapy; PD = Patient Days; 
Zosyn = Piperacillin-tazobactam
Table 3: Secondary outcomes
Table 4: Cost analysis outcomes






Total Cost of LOS per 
Patient for POR, $
67.4 M 63.5 M -3.9 M
Average Cost of LOS per 
Patient for POR, $
33,376 28,865 -4,511
Average Cost of LOS per Patient by Hospital, $
Hospital A 26,184 26,760 +576
Hospital B 64,942 48,015 -16,927
Hospital C 12,921 11,961 -960
Hospital D 32,791 31,115 -1,676
Hospital E 14,759 10,043 -4,716
Hospital F 28,540 25,205 -3,335
Hospital G 21,795 24,453 +2,658
Hospital H 11,795 13,555 +1,760








Ceftriaxone 43552.08 47090.16 +3568.08
Zosyn 28752.02 25368 -3389.02
Meropenem 6550.68 6509.22 -41.46
Ceftazidime 704.94 386.58 -318.36
Cefepime 4012 4115.84 +103.84
Ciprofloxacin 901.33 911.71 +10.38
Levofloxacin 552.23 336.14 -216.09
Abbreviations: POR = Providence Oregon Region; LOS = Length of Stay; 
DOT = Days of Therapy; PD = Patient Days
Health & Services
Table 1: Patient baseline demographics
Figure 1: Empiric ceftriaxone usage by month 
Figure 2: Empiric IV anti-pseudomonal agent usage by month
